Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction vs Consolidation ChemoRT with Cisplatin/Docetaxel in NSCLC
NCT00633568Phase 3Terminated
- Sponsor
- European Lung Cancer Working Party
- Start
- Jan 2007
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of cisplatin and docetaxel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by European Lung Cancer Working Party. Primary endpoint: Overall Survival. Started Jan 2007; status: terminated.
02
Drugs
cisplatindocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00633568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00633568.